Bone-Targeting Systems to Systemically Deliver Therapeutics to Bone Fractures for Accelerated Healing
Autor: | Stewart A. Low, Jeffery J Nielsen |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
medicine.medical_specialty Amino Acids Acidic Recombinant Fusion Proteins Endocrinology Diabetes and Metabolism Osteoporosis 030209 endocrinology & metabolism Bone healing Article Fractures Bone 03 medical and health sciences Anabolic Agents Drug Delivery Systems 0302 clinical medicine Humans Medicine Fracture Healing Diphosphonates Tartrate-Resistant Acid Phosphatase business.industry Osteomyelitis Bone fracture Tetracycline Alkaline Phosphatase medicine.disease Durapatite 030104 developmental biology Bone targeting Targeted drug delivery Immunoglobulin G Orthopedic surgery Cancer research Systemic administration business Oligopeptides |
Zdroj: | Curr Osteoporos Rep |
ISSN: | 1544-2241 1544-1873 |
DOI: | 10.1007/s11914-020-00604-4 |
Popis: | PURPOSE OF REVIEW: Compared to the current standard of implanting bone anabolics for fracture repair, bone fracture targeted anabolics would be more effective, less invasive, less toxic and would allow for control over what phase of fracture healing is being affected. We therefore sought to identify the optimal bone targeting molecule to allow for systemic administration of therapeutics to bone fractures. RECENT FINDINGS: We found that many bone targeting molecules exist, but most have been developed for the treatment of bone cancers, osteomyelitis, or osteoporosis. There are a few examples of bone targeting ligands that have been developed for bone fractures that are selective for the bone fracture over the body and skeleton. SUMMARY: Acidic oligopeptides have the ideal half-life, toxicity profile, and selectivity for a bone fracture targeting ligand and are the most developed and promising of these bone fracture targeting ligands. However, many other promising ligands have been developed that could be used for bone fractures. |
Databáze: | OpenAIRE |
Externí odkaz: |